Chloraquine
Categorie
Chloraquine Les marques, Chloraquine Analogs
- 3377 RP opalate
- Amokin
- Aralen
- Aralen HCl
- Arechin
- Arthrochin
- Artrichin
- Avlochlor
- Avloclor
- Bemaco
- Bemaphate
- Bemasulph
- Benaquin
- Bipiquin
- Capquin
- Chemochin
- Chingamin
- Chloraquine
- Chlorochin
- Chlorochine
- Chloroquina
- Chloroquine (VAN)
- Chloroquine Phosphate
- Chloroquinium
- Chlorquin
- Cidanchin
- Clorochina
- Cocartrit
- Delagil
- Dichinalex
- Elestol
- Gontochin
- Heliopar
- Hydroxychloroquine Sulfate
- Imagon
- Iroquine
- Klorokin
- Lapaquin
- Malaquin
- Malaren
- Malarex
- Mesylith
- Neochin
- Nivachine
- Nivaquine
- Nivaquine B
- Nivaquine [as sulfate]
- Pfizerquine
- Plaquenil
- Quinachlor
- Quinagamin
- Quinagamine
- Quinercyl
- Quingamine
- Quinilon
- Quinoscan
- Resochen
- Resochin
- Resoquina
- Resoquine
- Reumachlor
- Reumaquin
- Roquine
- Sanoquin
- Silbesan
- Siragan
- Solprina
- Sopaquin
- Tanakan
- Tresochin
- Trochin
Chloraquine Les marques melange
Chloraquine Formule chimique
C18H26ClN3
Chloraquine RX lien
http://www.rxlist.com/cgi/generic2/hquine2.htm
Chloraquine FDA fiche
Chloraquine msds (fiche de securite des materiaux)
Chloraquine Synthese de reference
Aucune information disponible
Chloraquine Poids moleculaire
319.872 g/mol
Chloraquine Point de fusion
289 oC
Chloraquine H2O Solubilite
10,6 mg / L
Chloraquine Etat
Solid
Chloraquine LogP
4.474
Chloraquine Formes pharmaceutiques
Tablet
Chloraquine Indication
Pour le traitement suppressif et de crises aiguës de paludisme à P. vivax, P. malariae, P. ovale et des souches sensibles de P. falciparum, l'agent de deuxième ligne dans le traitement de la polyarthrite rhumatoïde
Chloraquine Pharmacologie
La chloroquine est le prototype de médicament anti paludisme, la plus largement utilisée pour traiter tous les types de paludisme, sauf pour les maladies causées par la chloroquine de Plasmodium falciparum résistant. Il est très efficace contre les formes érythrocytaires de Plasmodium vivax, Plasmodium ovale et Plasmodium malariae, les souches sensibles de Plasmodium falciparum et des gamétocytes de Plasmodium vivax. Etre alcalin, le médicament atteint forte concentration dans les vacuoles alimentaires du parasite et soulève son pH. Il se trouve à induire l'agglutination rapide du pigment. La chloroquine inhibe l'enzyme polymérase parasitaires hème qui convertit l'hème toxiques dans non toxique hemazoin, ce qui entraîne l'accumulation de toxiques dans l'hème du parasite. Il peut également interférer avec la biosynthèse des acides nucléiques.
Chloraquine Absorption
Complètement absorbé par les voies gastro-intestinales
Chloraquine Toxicite
Aucune information disponible
Chloraquine Information pour les patients
PATIENT INFORMATION
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.
Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.
Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.
Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.
Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.
Follow Rxlist link and drugs.com link for detailed patient information.
Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.
In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.
Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.
Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.
Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.
Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.
Follow Rxlist link and drugs.com link for detailed patient information.
Chloraquine Organismes affectes
Plasmodium
